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The gastrointestinal tract of mammals hosts a high and diverse number of different microor-
ganisms, known as intestinal microbiota. Many probiotics were originally isolated from the
gastrointestinal tract, and they were defined by the Food and Agriculture Organization of the
United Nations (FAO)/WHO as “live microorganisms which when administered in adequate
amounts confer a health benefit on the host.” Probiotics exert their beneficial effects on the
host through four main mechanisms: interference with potential pathogens, improvement of
barrier function, immunomodulation and production of neurotransmitters, and their host tar-
gets vary from the resident microbiota to cellular components of the gut–brain axis. However,
in spite of the wide array of beneficial mechanisms deployed by probiotic bacteria, relatively
few effects have been supported by clinical data. In this regard, different probiotic strains have
been effective in antibiotic-associated diarrhea or inflammatory bowel disease for instance.
The aim of this review was to compile the molecular mechanisms underlying the beneficial
effects of probiotics, mainly through their interaction with the intestinal microbiota and with
the intestinal mucosa. The specific benefits discussed in this paper include among others those
elicited directly through dietary modulation of the human gut microbiota.
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1 Introduction
The gastrointestinal tract (GIT) of mammals hosts a high
and diverse number of different microorganisms, known as
intestinal microbiota. Bacteria, Archea, fungi protozoa, and
viruses cohabit and interact mutually and with the host, no-
tably with epithelial and immune cells. Gut microbe popula-
tions have achieved a more or less defined configuration dur-
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ing human evolution, which has facilitated the establishment
of mutualist relationships with the host [1]. During the last 10
years, development of next generation DNA sequencing plat-
forms has allowed a deep understanding of the composition
of the microbial populations inhabiting not only the gut, but
other locations in the body, such as the upper airways of the
respiratory tract, the skin, the mouth, or the vagina. Given
the metabolic potential encoded into the genes harbored by
our intestinal microbiota, at least 50-fold more unique genes
than our own human genes, many researchers are beginning
to consider our intestinal microbiota as another organ of the
human body. Indeed, our gut microbes are implicated in the
normal physiology of our GIT, and alterations in the relative
amounts of their populations can disrupt the beneficial inter-
actions between microbiota and host, having a direct effect
on human health [2].
Different functions are being attributed to the intestinal
microbiota in light of the research conducted mainly in the
last 10 years, among which (i) maintenance of the epithelial
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barrier, (ii) inhibition of pathogen adhesion to intestinal sur-
faces, (iii) modulation and proper maturation of the immune
system, (iv) degradation of otherwise nondigestible carbon
sources such as plant polysaccharides, and (v) production of
different metabolites such as vitamins and SCFAs, are note-
worthy. Perhaps the best indication of the beneficial influence
of the intestinal microbiota over the host has been obtained
from germ-free animals, in which the absence of microorgan-
isms colonizing their digestive tube ends in an immature
immune system and an aberrant GIT [3]. For instance, the
number of Peyer’s patches is lower, as well as the number of
colonic crypts, intraepithelial lymphocytes, Goblet cells, and
therefore a thinnermucus layer; contrary to this the caecum is
notably increased in volume with respect to standard animals
[4]. However, these models display several limitations, no-
tably the absence of a mature immune system, which might
influence the functionality of the gutmicrobiota. In germ-free
animals, withdrawal of sterile conditions or fecal transplan-
tation are ways of inducing immune system maturation [5].
During the last few years, some multidisciplinary initia-
tives have notably contributed to our understanding of the
gut microbiota, among which large collaborative projects,
such as the MetaHit project (http://www.metahit.eu/), the
Human Microbiome Project (http://hmpdacc.org/), or the
MyNewGut project (http://www.mynewgut.eu/). Research
conducted in the framework of these projects has generated
enough evidence to provide a qualitative change in the im-
portance of our gut microbes, mainly by the characterization
of the microbial communities associated to different human
diseases and the definition of environmental factors affecting
their dynamics, as well as by the creation of a genetic cata-
logue compiling all reference genes of microbial origin [6–9]
(http://gigadb.org/dataset/view/id/100064).
In this regard, there is a great deal of controversy about
what is the proper composition of the human gut micro-
biota, mainly because there is high interindividual variability
in terms of microbial abundances and because the relative
proportions of our intestinal microbes are highly influenced
by environmental factors, such as dietary patterns and other
habits [10]. In addition, intestinal microbiota is composed
of autochthonous members colonizing the gut mucosa, and
transient microbiota which is part of the ingested foods. It
has been estimated that the gut microbiota in each indi-
vidual comprises more than 100 different species. Overall,
about 1500 different species have been identified so far as
being part of the human gut microbiota. A total number of
1013–1014 total microbial cells constitute the intestinal micro-
biota, and it has been largely assumed that it represents ten
timesmore cells than our own eukaryotic cells. However, this
ratio is considered nowadays exaggerated, as for instance if
we take into account the number of red cells, which has no
nucleus, the 10:1 ratio looks to be more like 1:1 [11]. On the
contrary, defecation may flip this proportion to 10:1 again,
making this topic hot and controversial as a part of readers
may consider a red cell to be an eukaryotic cell, while the other
part will consider them differentiated cells that lose their nu-
cleus to maximize their capacity to transport oxygen. The
large intestine is by far the body location with the highest
microbial concentration, about 1011–1012 cells/g of intesti-
nal content, representing 50–60% of the dry weight of feces
[12]. Bacteria dominate the gut microbiota, being represented
principally by the phyla Firmicutes and Bacteroidetes, and by
secondary phyla such as Actinobacteria, Proteobacteria, Syn-
ergistetes, Fusobacteria, and Verrucomicrobia [13]. Fungi and
Archea represent up to 1% of the species of the human gut
microbiota [14]. Among the main representative genera of
these phyla, Bacteroides sp., Faecalibacterium sp., Blautia sp.,
Prevotella sp.,Clostridium sp.,Ruminococcus sp., andBifidobac-
terium sp. (in breast-fed infants) are noteworthy due to their
high relative abundance, and indeed each and every one of
us harbors several grams of one or more of these bacterial
genera [9, 15].
Recently, it has been proposed that all the interindividual
variability of the intestinal microbiota could be classified into
three groups, the so called enterotypes, which are defined as
a network of coabundant microbial populations dominated
by the prominent presence of one of these three genera: Ru-
minococcus, Bacteroides, and Prevotella [16]. This classification
has been a source of controversy, as some authors consider
enterotypes a very simplistic model, reducing the whole in-
testinal microbiota complexity into three groups [17]. For in-
stance, some authors have found just two of these enterotypes
[18] as two continuous clusters of microbiota configurations
separated by a gradient of species with variable abundances
[19].
Therefore, considering the complexity of intestinal micro-
biota, it is unlikely that the diversity could be fitted into sim-
ple classification systems such as enterotypes. Categorizing
the intestinal microbiota into enterotypes or other groups,
with strong correlations with dietary patterns, could be ex-
tremely helpful in personalizing the treatment of diseases
progressing with microbial dysbiosis [20]. This will require
development of mathematical models able to condense the
whole complexity, and therefore more experimental data are
needed [21].
2 The probiotic concept—Evolution
Today the characterization of intestinal microbiota composi-
tion and activity is a hot topic for scientists working at the
intersection of the fields of human Microbiology, Immunol-
ogy and Health, and it has a direct connection with research
on probiotic bacteria. Since ancient times fermented prod-
ucts containing living microorganisms have been used to
restore or maintain health. This was already acknowledged in
a version of the Old Testament that attributed the longevity
of Abraham to the consumption of sour milk [22]. More re-
cently, at the beginning of the last century, the Nobel laure-
ate Russian immunologist E´lie Metchnikoff introduced the
idea of consuming beneficial livemicroorganisms to improve
health. Metchnikoff proposed that eating fermented milks
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containing lactobacilli might displace putrefactive and
pathogenic intestinal organisms and increase longevity [23].
This could be considered as the first reference to our current
understanding of the probiotic concept.
Although the probiotic concept seems to be old, the term
“probiotic” was not defined until recently. The first use of
the term is attributed to Lilly and Stillwell who, in a paper
published in Science in 1965, defined probiotics as “growth-
promoting factors produced by microorganisms” [24]. In opposi-
tion to antibiotics, Lilly and Stillwell used this term to refer to
substances produced by one microorganism stimulating the
growth of others.
The first definition of probiotics, within the conceptual
framework initiated by Metchnikoff, was that of Parker [25],
who defined probiotics as “organisms and substances which con-
tribute to intestinalmicrobial balance”. A decade later, following
the same concept but narrowing it to live microorganisms,
Fuller proposed the definition “live microbial feed supplements
which beneficially affect the host animal by improving its intesti-
nal microbial balance” [26]. A few years later, to underline the
microbial nature of probiotics and to explicitly cover any body
habitat also in humans, a new definition was proposed as
“viable mono- or mixed culture of microorganisms which, applied
to animals or man, beneficially affects the host by improving the
properties of the indigenous microflora” [27]. All these defini-
tions have in common a focus on the effect upon the intesti-
nal microbiota. However, there were an increasing number
of scientific studies showing effects of probiotics not related
to the intestinal microbiota, such as those demonstrating im-
mune modulating capabilities. This led to the simultaneous
proposition of two new definitions of probiotics as “live micro-
bial culture or cultured dairy product which beneficially influences
the health and nutrition of the host” [28] and as “living microor-
ganisms which upon ingestion in certain numbers, exert health
benefits beyond inherent basic nutrition” [29].
In this context the International Life Sciences Institute
Europe (ILSI) tried to find a consensus definition and in 1998
a working group of experts proposed the definition “viable mi-
crobial food supplement which beneficially influences the health
of the host” [30]. The same working group defined probiotic
foods as functional if they “have been satisfactorily demonstrated
to beneficially affect one or more target functions in the body be-
yond adequate nutritional effects, in a way that is relevant to either
an improved state of health and well-being and/or reduction in
the risk of diseases” [31]. Definitions covering dead bacteria and
bacterial components were also proposed, such as “microbial
cell preparations or components of microbial cells that have a ben-
eficial effect on the health and well-being of the host” [32]. This
definition did not require viable bacteria and was based on
studies showing that non-viable bacteria and bacterial compo-
nents (e.g. DNA) also produce some beneficial effects [33,34].
Attempts to find a consensus definition finally came to an
end when in 2001 a panel of experts convened by the Food
and Agriculture Organization of the United Nations (FAO)/
World Health Organization (WHO) proposed to define pro-
biotics as “live microorganisms which when administered in ad-
equate amounts confer a health benefit on the host” [35]. This
definition was compiled together with recommendations re-
garding probiotic research in a guideline issued in 2012 by
the FAO/WHO working group, and seems to have received
enough quorum and consensus. This definition has been
widely accepted since then and has been subjected only to
a minor grammatical modification “live microorganisms that,
when administered in adequate amounts, confer a health bene-
fit on the host” [36]. According to this definition, which cov-
ers well our current probiotic concept, being a probiotic is a
strain-specific characteristic. Thus, the properties of each pro-
biotic strain should bewell defined and cannot be extrapolated
to other strains. It is necessary to scientifically demonstrate
the efficacy of the strain in conferring a health benefit on the
host, but this effect does not have to be linked to any specific
mechanism of action.
The concept is not restricted to foods, allowing for other de-
livery options such as pharmaceutical preparations and other
scenarios such as extra intestinal locations such as respiratory
tract, skin, blood, genitourinary tracts etc. It does not involve
an oral application either, allowing other delivery routes and
topic application. Moreover, according to the current defini-
tion a probiotic must be alive, viable bacteria, and it is not
applicable to dead bacterial cells or cell components. This
FAO/WHO definition has been adopted by several organi-
zations such as the International Scientific Association for
Probiotics and Prebiotics (ISAPP), Codex, Institute of Food
Technologists (IFT), World Gastroenterology Organization
(WGO), or the European Food Safety Authority (EFSA) [36].
3 Evidence-based probiotic effects on
intestinal diseases
A large number of disease states and intestinal disorders have
been related to an unbalanced GIT microbiota. Scientific evi-
dence supports the important roles that probiotics can play in
the digestive system, having significant effects in alleviating
the symptoms of several diseases [37]. This section reports on
scientific evidence of benefit from probiotics for specific in-
testinal diseases, the main target of probiotic intervention. It
summarizes the main illnesses of the GIT for which restora-
tion of the microbial balance by the use of probiotics has
evidenced beneficial health effects in the prevention or treat-
ment of disease.
(i) Infectious diarrhea.
Of the various microorganisms that cause infectious di-
arrhea, rotavirus is the most common case in infants.
Acute diarrhea is also frequent among travelers, in whom
enterotoxigenic Escherichia coli is particularly common.
Other important diarrheogenic bacterial pathogens are
members of the genera Salmonella, Campylobacter, and
Shigella. The rationale for using probiotics in infec-
tious diarrhea is that they act against enteric pathogens
by competing for available nutrients and binding sites,
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making the gut contents acid, producing a variety of
chemicals, and increasing specific and nonspecific im-
mune responses. Probiotics have been tried in a large
number of clinical studies as a supplement to rehydra-
tion therapy in the treatment of infectious diarrhea. The
results have been positive and remarkably consistent in
shortening the duration and reducing stool frequency [38].
Although increasing numbers of travelers are also consid-
ering the use of probiotics as a preventive, there are fewer
studies on adults and they are less conclusive [37, 39].
However, the European Society for Paediatric Gastroen-
terology Hepatology and Nutrition (ESPGHAN) recom-
mends consideration of probiotic administration in ad-
dition to rehydration as therapy for acute gastroenteritis
in children: Lactobacillus rhamnosus GG, Saccharomyces
boulardii and Lactobacillus reuteri DSM 17938, although
the latter has very low quality of evidence according to the
ESPGHAN report [40]. The World Allergy Organization
(WAO) recently published their Guidelines for Allergic
Disease Prevention (GLAD-P) based on the use of probi-
otics [41]. The WAO published recommendations about
the use of probiotics in the prevention on allergy, based on
scientific evidence and from the results of human trials.
These guidelines conclude that currently there is no evi-
dence supporting probiotic supplementation for reducing
the risk of allergy incidence in children. However, there is
likely net benefit using probiotics for eczema prevention,
which requiresmore clinical trials to increase sample size.
On the contrary, WAO suggests the use of probiotics in
pregnant women, in women who breastfeed their infants
and in the own infants, in all those cases where a family
history of allergy (eczema) is identified as factor risk for
children [41].
(ii) Antibiotic-associated diarrhea (AAD).
Antimicrobial therapy disturbs the endogenous GIT mi-
crobiota, frequently resulting in diarrhea. In the majority
of the cases, this diarrhea is related to the overgrowth ofC.
difficile causing what is called C. difficile–associated diar-
rhea (CDAD). The increasingnumber of clinical studies in
recent years provided data formeta-analyses testing the ef-
ficacy of probiotics (mainly the strain LactobacillusGGand
the yeast species S. boulardii) in the protection and relapse
of CDAD. Recent systematic reviews with meta-analysis
showed the effectivity of these probiotics in preventing
AAD in both children and adults [42,43]. The ESPGHAN
Probiotic Group does not recommend the use of probi-
otics for the treatment of AAD, as not enough randomized
controlled trials are available. However, administration of
probiotics for preventing AAD is recommended if some
risk factors such as duration of the antibiotic treatment or
comorbidities are present. In these cases, administration
of L. rhamnosus GG and S. boulardii is strongly recom-
mended by the ESPGHAN [44]. In the case of CDAD,
and although the ESPGHAN consider administration of
S. boulardii, fecal microbiota transplantation appears as a
powerful treatment for the definitive eradication of this
pathogen from the human gut [45].
(iii) Inflammatory bowel disease (IBD).
IBD includes Crohn’s disease, ulcerative colitis (UC),
and pouchitis, which are characterized by deregulation
of the immune system leading to inflammation of the
GIT. A disturbance in the GIT microbiota, or an inad-
equate host response to it, has been shown to play a
critical role in the pathogenesis of IBD. Probiotics can
influence both the GIT microbiota and the immune
system and many experts in the field of IBD are us-
ing probiotics to treat IBD patients. The greatest evi-
dence for efficacy of probiotics in these pathologies is
in its use (in particular the formulation of multiple
strains VSL3) for the prevention of pouchitis [46]. Tri-
als examining the use of probiotics with Crohn’s dis-
ease have been rather disappointing, while the evidence
of benefit from probiotics in UC is quite promising
[47].
(iv) Irritable bowel syndrome (IBS).
IBS is characterized by abdominal discomfort or pain and
altered bowel function. Although the causes of IBS are not
completely understood, growing evidence suggests a po-
tential role of intestinal microbiota in its pathophysiology
and symptom generation. For that, different probiotic in-
tervention studies have been performed in last few years
and although the results suggest that there is a benefit of
probiotic use in the relief of IBS symptoms [37, 48], well-
designed, placebo-controlled studies are recommended
since each probiotic strain has unique features and IBS
patients are heterogeneous [49].
(v) Helicobacter pylori infection.
Helicobacter pylori, a highly prevalent pathogen, is a major
cause of chronic gastritis and peptic ulcers and a risk fac-
tor for gastric malignancies. Interventional studies using
probiotics alone have not resulted in eradication ofH. py-
lori. However, several trials have found that if probiotics
are used in conjunction with the standard therapy, the
rate of eradication is improved. Furthermore, probiotics
(such as S. boulardii, L. reuteri, and L. rhamnosus GG) can
help by preventing gastrointestinal antibiotic associated
side effects [50, 51].
(vi) Lactose intolerance.
A large part of the world population shows low levels
of the enzyme -galactosidase (lactase) in the mucosa
of the small intestine. These individuals suffer intoler-
ance symptoms when milk (lactose) is present in their
diet. There is good scientific evidence for the allevia-
tion of lactose intolerance symptoms by the consump-
tion of yogurt and fermented milk products contain-
ing conventional lactic acid bacteria as starter cultures
and probiotic bacteria [52]. These are thought to confer
beneficial effects by providing microbial -galactosidase
activity that improves tolerance and digestibility of
lactose.
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Figure 1. On the left, beneficial
effects attributed to probiotics,
according to the expert consen-
sus document of The Interna-
tional Scientific Association for
Probiotics and Prebiotics [36].
Some of these are widespread
among probiotic strains, such
as production of SCFAs or nor-
malization of perturbed micro-
biota, whereas others are strain
specific, such as immunomod-
ulation. On the right, beneficial
probiotic effects on different dis-
orders as supported by results
from clinical trials.
4 Host–probiotic
interaction—Mechanisms involved
The probiotic microorganisms most commonly used in hu-
man nutrition are certain strains belonging to the genus Lac-
tobacillus,Bifidobacterium, Enterococcus as well as strains from
the genus Propionibacterium and certain yeasts such as S.
boulardii [53]. During recent years, a high number of stud-
ies using animal models and clinical interventions have ex-
plored the potential benefits of probiotics on human health,
mainly in the prevention and treatment of several diseases
[54]. Probiotics exert their benefits through four different
mechanisms of action: (i) interference with pathogenic bac-
teria by competing with nutrients and adhesion sites, (ii)
improvement of the barrier function of the epithelial lining,
(iii) immunomodulation, and (iv) influence on other organs
of the body through the immune system and neurotrans-
mitter production (such as -aminobutyric acid (GABA) or
serotonin) (Fig. 1) [36]. For instance, probiotics should have
a high adherence ability to the intestinal epithelium, limiting
the access of enteropathogens to target molecules present
on the host cell surfaces that are used for initiating the pro-
cess of invasion. In addition, probiotics produce antimicro-
bial substances such as bacteriocins and SCFAs, inhibiting
the growth of potential pathogens. Intestinal microbiota and
some emerging probiotics have genes coding for proteins re-
sponsible for biochemical pathways not present in the human
host, such as degradation of complex carbon source or vita-
min and other essential compound production. For instance
some strains produce butyrate as a result of their fermenta-
tive metabolism, which is a key molecule in the maintenance
of the gut homeostasis notably at the level of epithelial cells.
Probiotics interact with the human host at three differ-
ent levels of the lower part of the human GIT: mucus layer,
epithelial layer, and gut-associated lymphoid tissue (GALT)
(Fig. 2). The mucus layer is in turn subdivided into two sec-
tions, an outer sublayer in which the mucin molecules form
a quite relaxed gel, which is characterized by the presence
of relatively high numbers of bacteria, as well as by the pres-
ence of antimicrobial peptides and secreted immunoglobulin
A, aimed at limiting the amount of commensal bacteria colo-
nizing this location. Contrary to this, there is an inner, dense,
and compact mucin sublayer immediately adjacent to the ep-
ithelial cells, restricting access to the bacteria, and where few,
or no, microorganisms are observed [55, 56].
The second level of interaction of probiotics with the
human host is epithelial cells. Different cell subpopulations
configure the epithelial cell monolayers that line the whole
intestine lumen: enterocytes and colonocytes specialized
in nutrient absorption, Goblet cells specialized in mucin
secretion, the major components of mucus, Paneth cells,
which release a set of antimicrobial molecules such as
defensins (for instance the antimicrobial peptide Reg III)
and lysozyme, and finally M cells, which are a kind of cellular
mediator between the molecules/microorganisms present in
the intestinal lumen and the innate immunity, and which
are specialized in transepithelial transport [57]. Interaction
of probiotics at this level is very important to keep the barrier
function, this being achieved by reinforcing the so-called
tight junctions, special locations in which the membranes of
two adjacent epithelial cells join together, sealing the lateral
surfaces of the enterocytes.
Finally, one of the major points of interaction between
probiotics and the human host is the GALT. This is one
of the mucosal associated lymphoid tissues of the human
body and, in the lower part of the GIT, is composed mainly
of Peyer’s patches and lymphoid/plasma cells that are dif-
fusely distributed throughout the gutmucosa. Peyer’s patches
are GALT locations specialized in immune surveillance. In
this place antigen-presenting cells, such as dendritic cells
or macrophages, interact with T and B cells after direct
or M-cell-mediated sampling of the intestinal content [58].
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Figure 2. Diagram representing
the main mechanisms of action
of probiotics. Mechanisms, bio-
logical processes, and host cells
responsible for the interaction
are shown color coded.
Probiotics, as with other bacteria, have a set of relatively well-
conserved molecules known as microbial-associated molec-
ular patterns. They interact with specific pattern-recognition
receptors present on the surface or in the organelle mem-
brane of epithelial and dendritic cells, this interaction being
responsible for not only some of the beneficial effects at-
tributed to probiotics, but also key for the normal interaction
of the intestinal microbiota with the human host [59].
Some of the receptor families present on immune and
epithelial cells are Toll-like receptors, Nod-like receptors or
C-type lectin receptors, and RIG-I-like receptors. Interac-
tion of microbial-associated molecular patterns with pattern-
recognition receptors determine maturation of antigen-
presenting cells, which will subsequently define the type of
the immune response developed, whichmay bemainly effec-
tor (Th1, Th2, or Th17) or regulatory (Treg).
Treg response is directly related to the maintenance of in-
testinal homeostasis and the development of tolerance to-
ward the resident microbiota [60]. Probiotics inducing the
Treg response are of paramount importance, notably in the
framework of IBD and other inflammatory diseases. It has
been observed in germ-free animals that colonization with
a model microbiota induces both the recruitment and pro-
duction of Treg cells in the intestinal mucosa, being essential
to maintain a low inflammation grade in the gut mucosa.
Some probiotic bacteria such as members of the genus Lac-
tobacillus may promote this beneficial process through the
production of immunomodulatory peptides, such as peptide
STp. This peptide acts by inducing an anti-inflammatory cy-
tokine profile in dendritic cells, while downregulating inflam-
matory mediators, both in healthy controls and UC patients
[61,62]. Induction of theTreg response has also been observed
in some members of the Clostridium clusters IV, XIVa, and
XVIII, where some of the strains are claimed to be emerging
probiotics [63]. In this case, the homeostatic effect of these
bacteria is supported by the production of SCFAs, notably
butyrate.
Apart from the direct contact with mucosa, soluble factors
synthesized by probotic bacteria are able to stimulate host
responses. In this regard, butyrate producers play a key role
in the maintenance of the epithelial barrier, since butyrate
is one of the main energy sources of enterocytes [64]. Also,
a 15 kDa protein secreted by Faecalibacterium prausnitzii is
able to inhibit the NF-B pathway in intestinal epithelial cells
and to prevent colitis in an animal model [65]. The reader
is prompt to other reviews dealing with the role of soluble
factors produced by the intestinal microbiota with a potential
role in the molecular cross-talking with the human host [66].
5 Gut microbiota modulation as a target
for dietary interventions using
probiotics
The ultimate goal of a probiotic dietary intervention is to
have a positive effect on the health of the target popula-
tion. This could be achieved through different actions, such
as modulation of immunological responses, amelioration of
the nutritional state of the host, or those derived from the
modulation of the gut microbiota. For many years, it was
generally accepted that the majority of the desired probiotic
effects were associated with microbial ecological changes in
the gut. In this regard, some preclinical studies in animal
models have shown that the introduction of Bifidobacterium
or Lactobacillus strains in the gut environment of mice, us-
ing different animalmodels, clearly impact on themicrobiota
composition of themurine gut [67–70]. However, recent liter-
ature indicates that these microbiota modifications are not so
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evident in humans, suggesting that bacterial metabolic shifts,
rather than a different representation of the microbial pop-
ulations, could play a pivotal role in the final physiological
outcome. In this regard, researchers have taken advantage
of novel omics techniques, mainly metagenomics, metatran-
scriptomics and metabolomics, to unravel the physiological
and ecological processes underlying the observed probiotic
effects in humans.
One of the most relevant studies was performed by Mc-
Nulty et al. [71]. In this work, the fecal microbiomes and
metatranscriptomes of adult female monozygotic twins were
characterized prior to, during and following the consump-
tion of a commercially available fermented milk containing,
among othermicroorganisms, a strain of Bifidobacterium ani-
malis subsp. lactiswith attributed health effects. Surprisingly,
the bacterial species composition did not significantly change
during the course of the study. However, significant changes
were detected in the human fecal metatranscriptome during
the period of fermented milk consumption, especially those
related with the metabolism of plant polysaccharides. Also, a
probiotic cheese containing two Lactobacillus strains from the
species Lactobacillus rhamnosus and Lactobacillus acidophilus
did not significantly modify the levels of the major microbial
groups in an elderly population, although some significant
changes were observed in minority populations [72]. In a
different work, administration of L. acidophilus NCFM and
B. animalis subsp. lactis Bi-07 did not alter the global com-
position of the main bacterial groups present in the fecal
microbiota of children with atopic dermatitis [73].
In contrast to these observations, other studies have shown
that probiotics can cause a shift in specific bacterial pop-
ulations, with or without associated microbiota metabolic
changes. For instance, using high-throughput 16S riboso-
mal RNA gene sequencing, Plaza-Dı´az et al. [74] showed that
ingestion of L. rhamnosus, Lactobacillus paracasei or Bifidobac-
terium breve strains by an adult population induced changes in
the fecal bacterial population. Also, Lactobacillus salivarius Ls-
33 was able to modify the fecal bacterial populations of obese
adolescents, including several Clostridium groups, although
the local concentration of SCFAs remained unaffected [75].
A few works have studied the role of different probiotic in-
terventions in the microbiota of patients with IBS. During
intervention with a multispecies probiotic supplementation
in IBS patients, the probiotic group showed fluctuations in
some clostridia populations that were stably maintained dur-
ing the intervention and these alterationswere correlatedwith
the alleviation of gastrointestinal symptoms [76]. Also, fer-
mented milk containing B. animalis subsp. lactis was able to
decrease the abundance of some harmful bacteria andmodify
the colonic SCFAs production [77]. Furthermore, the effects
of probiotic fermented milk on the fecal metabolome of adult
patients with IBS was evaluated through a clinical trial, but
no difference in the fecal metabolites of the patients in the
probiotic groups was detected [78].
Probiotics in combination with other active dietary com-
ponents also represent a very remarkable strategy to bene-
ficially affect host health. In this regard, synbiotics, that is
probitotic and prebiotic combinations, have been used [79].
Some of these synbiotics do not affect microbiota composi-
tion, but are able tomodify its metabolic profile. For instance,
synbiotic L. acidophilus NCFM and cellobiose does not affect
human gut bacterial diversity but increased the local concen-
tration of branched-chain fatty acids, which play a role in the
maintenance of gut physiology [80].
These studies highlight the need to use complementary
approaches to provide the necessary observations that could
explain the molecular principles underlying the probiotic ef-
fect. Themajority of the probiotic intervention studies involv-
ing next-generation sequencing (NGS) approaches and/or
metabolomics have shown that no relevant changes in the
gut microbiota structure are detected during or after the in-
tervention. However, we have to bear in mind that the effect
is strain specific, and may vary depending on the physiology
of the individuals and the dietary context in which the in-
terventions were performed [81]. Furthermore, there is clear
evidence that a shift in the local gut environment does not
necessarily involve changes in the bacterial populations and,
under some circumstances, probiotic-driven effects seem to
be related to a metabolic shift of the gut microbiota (for in-
stance, increase in SCFA production), rather than to a change
of the microbiota profile.
Interestingly probiotics develop relevant roles in terms of
cross-feeding activities when they enter in contact with the
rest of microbial communities, influencing the metabolic ca-
pacities of other commensalmembers. Great examples of this
can be found within the genus Bifidobacterium, which are im-
portant gut commensals with some probiotic representatives.
Bifidobacteria are able to metabolize different carbohydrates
originated from diet or from the host mucosa, producing dif-
ferent proportions of acetic/lactic acid through their specific
fermentative pathway [82]. Presence of a givenBifidobacterium
species may influence the metabolic activity of other species
through cross-feeding mechanisms and vice versa, as it was
observed in cocultures of different bifidobacteria species. On
the one hand, Bifidobacterium bifidum increases its metabolic
activity when cocultured in the presence of other species such
as B. breve [83]. On the other hand, B. breve benefits from
the sialic acid released from the B. bifidum metabolism on
host glycans, such as human milk oligosaccharides (more
concisely 3-sialyllactose) or mucin [84, 85]. This is a good ex-
ample on how bifidobacteria administered as probiotics may
affect the metabolic capacity of commensal gut populations
by affecting the way in which host glycans are metabolized.
Further, changes in the production of organic acids will affect
the metabolism of other microbial groups, such as butyrate-
producing bacteria [86].
Unlike gut microbiota, less attention has been paid to
the gut virome. It has been postulated that the number of
unique genes coding in the virome may be immense, as it
includes not only those that infect cells, but bacteriophages,
retroviruses, fungi viruses etc. [87]. Bacteriophages, or viruses
that infect commensal bacteria, are important means for
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microbiota modulation and they have been proposed to be
used for microbiota modulation by targeting specific com-
mensal groups, which may have a profound impact on the
immune response at the mucosa level [88]. For all these rea-
sons further research will likely elucidate some of the effects
of the gut virome not only in host disease, but as beneficial
modulators of gut physiology.
In this regard some probiotic interventions show a pivotal
role in the metabolic activity of intestinal microbiota. One of
the most relevant effects is the increase in intestinal butyrate
concentrations or butyrate-producing bacteria. A recent study
has shown that food-allergic infants fed with a L. rhamnosus
GG-supplemented formula increased the butyrate-producing
bacterial population in feces [89]. Also, Ferrario et al. [90]
showed an increase of some butyrate produces after intake
of a strain of L. paracasei, and suggest that fecal butyrate
concentrations could represent an important biomarker for
identifying subjects who may benefit from probiotic treat-
ment.
6 Can we associate beneficial effects to
specific microbes/microbial
populations?
Attempts have been made to define the microbial taxa that
constitute a healthy humangutmicrobiota.However, its com-
position is highly variable between different individuals due
to the strong influence that host and environmental factors
exert on the gut microbial ecosystem, making it extremely
difficult to establish a common “human core microbiome”
[91]. Thus, at the moment, the scientific community has not
reached a consensus to define our beneficial intestinal micro-
bial fingerprint. However, accumulating observational stud-
ies have shown that there is a correlation between some bac-
terial populations in the human gut microbiota and different
physiological states, including those having an influence on
health. One of the typical examples of this correlation is that
of bifidobacteria in breast-fed infants. Breast-feeding consti-
tutes the golden standard for infant nutrition and numerous
studies have shown its protective effect on immunological
disorders and infections [92]. Therefore, since bifidobacte-
ria populations are abundant in breast-fed infants, compared
with those fed with infant formula, it is generally believed
that the presence of bifidobacteria in the microbiota of in-
fants is an indicator of good health [93, 94]. On the other
hand, currently we know that aberrancies in the gut micro-
biota composition are associated with several diseases, in-
cluding chronic diseases such as type 2 diabetes or Crohn’s
disease [95, 96], immune-related disorders [97]. Consistently,
metagenomic studies have shown that specific groups of strict
gut anaerobes are underrepresented in disease states, such
as F. prausnitzii and other members of the Ruminococcaceae
family in Crohn’s disease [96, 98], or representatives of the
Clostridium XIVa cluster, including members of the Lach-
nospiraceae family, in a myriad of diseases [97–99].
Diseases in which the strict anaerobic population is de-
creased normally involve physiological conditions in which
inflammation and oxidative stress are present [100]. Unfor-
tunately, these “most wanted” taxa, those highly prevalent
and abundant in the human microbiota that appear to be
associated with a healthy state, or those that are depleted
in physiological disorders and/or diseases, are normally fas-
tidious or non-culturable anaerobes that do not grow using
traditional cultivation methods. This means that we know
of their existence and identity mainly because of the advent
and refinement of NGS methodologies, but we know very
little about their functions. Even using advanced massive
sequencing methods, some microbial groups (e.g. Archaea)
could pass totally unnoticed [101]. Therefore, in practice, the
physiology and metabolic capabilities of the majority of the
“healthy” microbial representatives of our gut have not been
studied yet, with a few exceptions, such as Bifidobacterium
and Lactobacillus strains, which grow relatively well under
laboratory conditions, or F. prausnitzii, one of the “emerging
probiotics” [102]. Thus, a pivotal activity in future probiotic re-
searchwill be to develop novelmicrobial cultivation strategies
of the nonculturable “potential” beneficial microbes that are
associated with healthy conditions in humans, either alone or
cocultivated in defined microbial consortia [103], which will
be critical for the food and pharma industry in order to be
able to perform disease-targeted probiotic interventions and
bring novel products to the market.
7 Bioinformatics gives the meaning
A way to investigate gut microbiota modulation is high-
throughput sequencing of the genes or a precise gene
fragment, usually a variable region of the 16 rDNA gene.
Metagenomes are an analytically challenging type of genomic
data, which encompass sequences of all genes from the total-
ity of a complex microbial community. Although NGS allows
the genomic analysis of samples obtained directly from the
environment, such an approach generates huge volumes of
data and demands a powerful means of analysis. Many gut
metagenomic studies still perform 16S rRNA sequencing,
but this approach do not allowmonitoring changes in themi-
nor players of the gut microbiota [101]. For this reason whole
shotgun sequencing is becoming the technology of choice
to perform sequence analysis and community comparison.
Either way, bioinformatics is a critical factor in these studies
(Fig. 3).
In terms of 16S rRNA gene analyses, the Genboree Mi-
crobiome Toolset supports community profiling (i.e. deter-
mination of the abundance of each type of microbe) [104],
QIIME [105], and Mothur [106] (also part of Genboree) can
be used to obtain quantitative insights into microbial ecol-
ogy, BLAST [107] and Cd-hit [108] facilitate the comparison
of large sets of proteins, and the Chimera Slayer is used to
detect sequences falsely interpreted as organisms (contribut-
ing to false perceptions of sample diversity and the false
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Figure 3. Schematic overview of the bioinformatics tools available for the study of probiotic and microbiota functionality, including
molecular databases, system biology tools, or in silico models of metabolic microorganism among others.
identification of novel taxa) [109]. Furthermore, the Riboso-
mal Database Project classifiers may help in the assignment
of rRNA sequences into bacterial taxonomy [110].
In whole genome studies, there is also a set of commonly
used tools. Bowtie2 tool [111] enables read alignment to the
human genome (reference) and to the KEGG database [112].
KEGG alignment results can be further analyzed by the HU-
MAnN system to determine the relative abundance of the
gut microbial functional pathways [113]. For example, lin-
ear discriminant analysis may help in identifying enzymatic
pathways that are significantly different between pre- and
postintervention [114].
IDBA-UD is utilized in de novo assembly of metagenomic
sequencing data [115]. Genes are clustered based on their
abundance data using the Canopy-based algorithm and the
profiles of these groups may be calculated as the sample-
wise median gene abundance [116]. Often, the HMP DACC
database supports the comparison of assemblies and ref-
erence genomes, performed using MUMmer3.0 [117] or a
similar tool. In turn, phylogenetic analysis is supported by
tools such as the CVTree server, which implements a whole
genome-based, alignment-free composition vector method
[118]; MetaPhlAn, which estimates the abundance of species
in each sample according to the number of mapped reads to
its markers [119]; and, SpecI, which is a method of group-
ing organisms into species clusters based on phylogenetic
marker genes [120]. These methods have been used, for in-
stance, to analyze how species within the same genome inter-
action groups decrease or increase their abundance together
during the dietary interventions [121].
The restoration or strengthening of the intestinal mi-
crobiota through diet-based approaches such as probiotics
has been proposed as a means to enhance relevant func-
tions of the GIT. Under this scenario, systems biology meth-
ods and tools provide an invaluable research workbench
to understand and model the metabolism and modulation
of intestinal microbiota. Arguably, the reconstruction of
genome-scale metabolic models and the elucidation of inter-
action networks are the two most prominent contributions
here.
Databases such as KEGG [122], Metacyc [123], Model
SEED [124] and Transporter Classification Database (TCDB)
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[125] are commonly used in metagenome reconstruction
projects, while the OptKnock algorithm [126] and the COBRA
toolbox [127] facilitate flux balance analysis and additional
metabolic profiling. For example, the analysis of a commu-
nity levelmetabolic networkmodel supported the discovery of
shifts associated with obesity and IBD [128]. The reconstruc-
tion of a genome-scale metabolic model for L. casei LC2W
enabled the identification of essential amino acids and vita-
mins and the exploration of the biosynthetic potential of some
metabolites [129]. The genome-scale metabolic reconstruc-
tion of Bifidobacterium adolescentis L2-32 and F. prausnitzii
A2-165 enabled in silico simulation of the metabolic cross-
talk between the two species and evidenced the importance
of acetate supply into butyrate production [130]. Additional
details on up-to-date genome-scale models of the human gut
microbiome may be found in ref. 131.
Computational pathway analysis, facilitated by tools
such as PathPred [132], is being utilized in the study of
community level biotransformation. For example, a meta-
metabolomenetwork coveringBacteroidetes, Firmicutes, and
Actinobacteria brought into light cross-feeding relationships
between some gut microbe enzymes and host carbohy-
drate metabolism enzymes [133]. Besides assessing host–
microbe symbiosis, pathway analysis offered interesting in-
sights into diet modulation and the use of probiotics in treat-
ingmetabolic disorders. Likewise, Booleannetworkmodeling
and dynamic analysis enable the inference of important re-
lationships within gut microbiota composition. More specif-
ically, this methodology was used to explore the dynamics of
clindamycin antibiotic treatment in C. difficile infection and
to predict therapeutic probiotic interventions to suppress C.
difficile infection [134].
The analysis of the interaction of bacterial genes and
dietary components is another valuable alternative. For ex-
ample, a protein–protein interaction network supported the
study of potential dietary interventions targeting the SCFA
metabolism, namely topological metrics enabled the iden-
tification of the most vulnerable protein targets of the bu-
tyrate and propionate metabolic pathways (i.e. protein tar-
gets are more likely to change gene expression activity) [135].
Within network-based studies, Cytoscape is the most used
platform to visualize and analyze interaction networks [136].
Besides providing generic means of visualization and topo-
logical exploration, this platform has a number of different
applications to enable multiscale data integration, data clus-
tering, enrichment analysis, andnetwork comparison, among
others.
In conclusion, bioinformatics and systems biology build
an excellent platform to generate theoreticalmodels to predict
how interventions with probiotics, bioactive compounds, or
specific diets can shape the structure and function of the
gut microbiota, thus inducing the desired host responses
under specific physiological conditions. They offer a range
of possibilities to develop novel microbial cultivation strate-
gies of “potential” beneficial microbes, which are associated
with healthy conditions in humans. Bioinformatics could also
allow the development of novel tailor-made substrates that
facilitate the enrichment of the beneficial bacteria within a
complex microbiota, through prediction of the nutritional
and environmental needs of these bacteria, among other po-
tential applications. However, until now, the physiological
validation of these theoretical models is still weak, and need
to be addressed more deeply in order to be able to perform
novel disease-targeted probiotic intervention strategies.
8 Conclusions and future perspectives in
probiotic research
Research on human diseases is revealing the vital roles played
by the gut microbiota. This interaction is not restricted to the
intestinal mucosa, but to distant locations such as the gut-
brain axis. Understanding the impact of the gut microbiota
on the host health is essential to design strategies focused in
their manipulation, notably in cases where altered microbial
patterns are present. Probiotics are important means to pro-
duce specific host benefits through different mechanisms,
among which modification of the intestinal microbiota is
noteworthy.However, recent literature suggests that themod-
ification of the intestinal microbiota is not strictly necessary
to produce a beneficial effect [137]. In fact, the probiotic effect
could be triggered via an interaction with the immune sys-
tem, which does not necessarily mean a modification of the
local microbial environment. In relation to this, during the
last years, it is becoming clear that some strains of the most
commonly used probiotics (belonging to the genera Lacto-
bacillus and Bifidobacterium) do not colonize the gut and are
released from the intestine after the probiotic intervention;
thus, they could not be considered stable members of the in-
testinal microbiota. Therefore, for future probiotic research,
we consider of key importance promoting studies on com-
mensal intestinalmicroorganisms, well adapted to the gut en-
vironment, that are able to modify the local microbial ecosys-
tem, thus potentially generating long-term effects. However,
the industrial exploitation of novel commensal strains be-
longing to nonconventional probiotic genera (i.e. Faecal-
ibacterium, Akkermansia, or Eubacterium) could be ham-
pered by the lack an appropriate regulatory frame and safety
studies.
On the other hand, in spite of our knowledge on themolec-
ular mechanisms underlying some of the beneficial effects of
probiotics, we are far of clinically prove their efficacy in many
inflammatory and autoimmune diseases. In the future, tech-
nological improvements for commensal gut microorganism
culture, coculture, and administration, together with safety
and clinical studies, will provide us with a new generation of
probiotics that are currently designed as “emerging.” More-
over, knowledge on the molecules responsible for the pro-
biotic effect will allow us to design new strategies allowing
culture, coculturing procedures, and propagation of these of-
ten fastidious and oxygen-sensitive bacteria.
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